This is a clinical trial that the investigators aim to validate In-vitro Activation (IVA) treatment protocol, which was previously defined by Kazuhiro Kawamura (MD) and Aaron Hsueh (PhD), in Turkish patient with Premature Ovarian Insufficiency (POI) under age 36.

The objectives of the study is as following;

• Validation of the previously defined In-Vitro Activation Protocol approach in Turkish patients under 36 years old with Premature Ovarian Insufficiency (POI).
• Giving an opportunity to young POI patient in Turkey for having genetically own baby.
• Primary outcome measure would be live birth.
• For activation of primordial follicles, phosphatase and tensin homolog (PTEN) inhibitor and protein kinase B (AKT) stimulator will be used.

Inclusion Criteria:

• Patient with POI
• Short amenorrhea period (1 - 2 years)

Exclusion Criteria:

• Having been treated with chemotherapy and/or radiotherapy;
• Having been diagnosed with advanced stage of endometriosis (endometriomas)
• Having been diagnosed with the chronic diseases such as diabetes, cardiac failure, kidney insufficiency, morbid obesity etc..
• Presence of chromosomal abnormality (Turner, Fragile-X etc.)
• Previous multiple laparotomies
• Menopause >10 years
• Accompanied azoospermia